RK-01: A Think-Outside-The-Box Approach To Durable Glycemic Control
Type 2 diabetes is characterized by pancreatic beta cell failure and insulin resistance. It continues to be an unmet medical need because currently marketed drugs are inadequate in meeting clinically the most important unmet medical need in the space: sustained glycemic control, with a focus on preserving beta cell function and decreasing insulin resistance.
~50% of newly diagnosed patients experience primary failure with Metformin (the current standard of care) and secondary failure with second and third add-on drugs in the United States (Montvida, O. et al. Diabetes Care 2018).
Mitigation of the underlying pathophysiology of beta-cell failure and insulin resistance is underserved by the current treatment options.
RK-01 is custom-designed and formulated to prevent beta cell failure and decrease insulin resistance. It is also expected to prevent primary failure of Metformin and secondary failure of add-on drugs.
Results obtained from animal studies as well as controlled clinical studies support the scientific rationale and the product concept.
Type 2 diabetes patients with high blood pressure (>85%) as well as arthritis as a coexisting condition (>47%) are underserved by the currently marketed drugs.
The U.S. FDA has approved ARKAY's IND application for evaluating RK-01 in adult obese type 2 diabetes patients with high blood pressure and arthritis.
Currently raising capital for the human clinical study.